Clinical pharmacokinetics of cefotiam.
Cefotiam, a semisynthetic parenteral cephalosporin of the aminothiazole group, exhibits interesting properties: stability against hepatic metabolism and excellent solubility, accounting for an apparent volume of distribution 2 to 3 times higher than that of most other cephalosporins. Its degree of protein binding is about 40%. High concentrations of cefotiam are observed in several tissues (kidney, heart, ear, prostate and genital tract) as well as in fluids and secretions (bile, ascitic fluid). In healthy subjects, the serum elimination half-life is about 1 hour. The pharmacokinetics are linear only for doses lower than 1g. Cefotiam is mostly (and rapidly) eliminated in unchanged form in urine; 50 to 70% of the dose is recovered during the 12 hours following administration, and only severe renal failure, with creatinine clearance less than 5 ml/min, significantly alters the elimination half-life. Although the drug has no proven nephrotoxicity in man, a reduction of the dose is recommended when creatinine clearance is less than 30 ml/min.
Brogard
J M
JM
Department of Internal Medicine, Hospital-University Centre of Strasbourg, Louis-Pasteur University, France.
Jehl
F
F
Willemin
B
B
Lamalle
A M
AM
Blickle
J F
JF
Monteil
H
H
D000375:Aging / Q000378:metabolism; D000818:Animals; D015310:Cefotiam / Q000493:pharmacokinetics*; D006801:Humans
D015310:Cefotiam